Advertisement

Journal of Neurology

, Volume 264, Issue 8, pp 1763–1767 | Cite as

Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS)

  • Thomas Kuczmarski
  • Elijah W. Stommel
  • Kristen Riley
  • Rup Tandan
  • Vinay Chaudhry
  • Lora Clawson
  • Tracie A. Caller
  • Patricia L. Henegan
  • Dominic N. Facciponte
  • Walter G. Bradley
  • Angeline S. AndrewEmail author
Original Communication

Abstract

A recent population-based analysis demonstrated lower risk of the lethal degenerative neuromuscular disease, amyotrophic lateral sclerosis (ALS) associated with history of the use of ‘antineoplastic agents’ and ‘immunosuppressants’. To see if this finding was generalizable to other ALS cohorts, we examined associations between use of these agents and ALS risk in an independent case–control study of n = 414 ALS patients and n = 361 controls in an Eastern US population. Controls were sampled from the general population and among non-neurodegenerative disease patients. A history of chemotherapy treatment was significantly associated with a decreased ALS risk (OR 0.46, 95% CI 0.22–0.89, P = 0.026). We did not observe an association between risk of ALS and immunosuppressant therapy use (OR 0.78, 95% CI 0.50–1.02, P = 0.23). Analyses were adjusted for age, gender, and smoking. Our results support the prior report for chemotherapy treatment and lead to further discussion of the underlying mechanism.

Keywords

Amyotrophic lateral sclerosis Case–control Chemotherapy Immunosuppressant Neurodegenerative 

Notes

Acknowledgements

We would like to thank the study participants and our sources of funding: ALS Association grants SC5181 and 15-IIP-213; Centers for Disease Control (CDC)/Agency for Toxic Substances and Disease Registry (ATSDR) R01TS1000245 and contract 200-2014-59046; the Dartmouth Clinical and Translational Science Institute, under award number UL1TR001086 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH).

Compliance with ethical standards

Ethical standards

All study procedures were approved by the Committee for Protection of Human Subjects at Dartmouth College, the Committee on Human Research in the Medical Sciences at the University of Vermont, and the Office of Human Subjects Research at Johns Hopkins Medicine. All data was collected from patients who consented to participation in the study.

Conflicts of interest

The authors declare that they have no conflict of interest.

Supplementary material

415_2017_8564_MOESM1_ESM.xlsx (10 kb)
Supplementary material 1 (XLSX 10 kb)

References

  1. 1.
    Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, Heverin M, Howard RS, Huisman MH, Keren N, Leigh PN, Mazzini L, Mora G, Orrell RW, Rooney J, Scott KM, Scotton WJ, Seelen M, Shaw CE, Sidle KS, Swingler R, Tsuda M, Veldink JH, Visser AE, van den Berg LH, Pearce N (2014) Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol 13(11):1108–1113. doi: 10.1016/S1474-4422(14)70219-4 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Seelen M, van Doormaal PT, Visser AE, Huisman MH, Roozekrans MH, de Jong SW, van der Kooi AJ, de Visser M, Voermans NC, Veldink JH, van den Berg LH (2014) Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol 261(10):1949–1956. doi: 10.1007/s00415-014-7445-1 CrossRefPubMedGoogle Scholar
  3. 3.
    Gibson SB, Abbott D, Farnham JM, Thai KK, McLean H, Figueroa KP, Bromberg MB, Pulst SM, Cannon-Albright L (2016) Population-based risks for cancer in patients with ALS. Neurology 87(3):289–294. doi: 10.1212/WNL.0000000000002757 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Costa J, Swash M, de Carvalho M (2012) Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. Arch Neurol 69(11):1410–1416. doi: 10.1001/archneurol.2012.254 CrossRefPubMedGoogle Scholar
  5. 5.
    Freedman DM, Travis LB, Gridley G, Kuncl RW (2005) Amyotrophic lateral sclerosis mortality in 1.9 million US cancer survivors. Neuroepidemiology 25(4):176–180. doi: 10.1159/000087447 CrossRefPubMedGoogle Scholar
  6. 6.
    Freedman DM, Curtis RE, Daugherty SE, Goedert JJ, Kuncl RW, Tucker MA (2013) The association between cancer and amyotrophic lateral sclerosis. Cancer Causes Control 24(1):55–60. doi: 10.1007/s10552-012-0089-5 CrossRefPubMedGoogle Scholar
  7. 7.
    Freedman DM, Wu J, Daugherty SE, Kuncl RW, Enewold LR, Pfeiffer RM (2014) The risk of amyotrophic lateral sclerosis after cancer in US elderly adults: a population-based prospective study. Int J Cancer 135(7):1745–1750. doi: 10.1002/ijc.28795 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Stoyanov A, Pamphlett R (2014) Is the risk of motor neuron disease increased or decreased after cancer? An Australian case-control study. PLoS One 9(7):e103572. doi: 10.1371/journal.pone.0103572 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Corcia P, Gordon PH, Camdessanche JP (2015) Is there a paraneoplastic ALS? Amyotroph Lateral Scler Frontotemporal Degener 16(3–4):252–257. doi: 10.3109/21678421.2014.965178 CrossRefPubMedGoogle Scholar
  10. 10.
    Crippa V, D’Agostino VG, Cristofani R, Rusmini P, Cicardi ME, Messi E, Loffredo R, Pancher M, Piccolella M, Galbiati M, Meroni M, Cereda C, Carra S, Provenzani A, Poletti A (2016) Transcriptional induction of the heat shock protein B8 mediates the clearance of misfolded proteins responsible for motor neuron diseases. Sci Rep 6:22827. doi: 10.1038/srep22827 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Banci L, Bertini I, Blazevits O, Calderone V, Cantini F, Mao J, Trapananti A, Vieru M, Amori I, Cozzolino M, Carri MT (2012) Interaction of cisplatin with human superoxide dismutase. J Am Chem Soc 134(16):7009–7014. doi: 10.1021/ja211591n CrossRefPubMedGoogle Scholar
  12. 12.
    Sathasivam S, Shaw PJ (2005) Apoptosis in amyotrophic lateral sclerosis—what is the evidence? Lancet Neurol 4(8):500–509. doi: 10.1016/S1474-4422(05)70142-3 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Thomas Kuczmarski
    • 1
  • Elijah W. Stommel
    • 1
  • Kristen Riley
    • 2
  • Rup Tandan
    • 3
  • Vinay Chaudhry
    • 2
  • Lora Clawson
    • 2
  • Tracie A. Caller
    • 4
  • Patricia L. Henegan
    • 1
  • Dominic N. Facciponte
    • 1
  • Walter G. Bradley
    • 5
  • Angeline S. Andrew
    • 1
    Email author
  1. 1.Department of NeurologyDartmouth-Hitchcock Medical CenterLebanonUSA
  2. 2.Department of Neurology, School of MedicineJohns Hopkins UniversityBaltimoreUSA
  3. 3.Department of Neurological SciencesUniversity of Vermont Medical CenterBurlingtonUSA
  4. 4.Cheyenne Regional Medical Center, Medical Specialty ClinicCheyenneUSA
  5. 5.Department of Neurology, Miller School of MedicineUniversity of MiamiMiamiUSA

Personalised recommendations